EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cochlear's enterprise value is A$20,494 Mil.
Cochlear's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$565 Mil. Therefore, Cochlear's EV-to-EBITDA for today is 36.30.
The historical rank and industry rank for Cochlear's EV-to-EBITDA or its related term are showing as below:
ASX:COH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.8 Med: 27.89 Max: 45.8
Current: 36.3
During the past 13 years, the highest EV-to-EBITDA of Cochlear was 45.80. The lowest was -79.80. And the median was 27.89.
ASX:COH's EV-to-EBITDA is ranked worse than 83.92% of 485
companies
in the Medical Devices & Instruments industry
Industry Median: 15.57
vs ASX:COH: 36.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-02), Cochlear's stock price is A$316.29.
Cochlear's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$5.321. Therefore, Cochlear's PE Ratio for today is 59.44.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Cochlear EV-to-EBITDA Historical Data
The historical data trend for Cochlear's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cochlear's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cochlear's EV-to-EBITDA falls into.
Cochlear EV-to-EBITDA Calculation
Cochlear's EV-to-EBITDA for today is calculated as:
Cochlear's current Enterprise Value is A$20,494 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cochlear's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$565 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (ASX:COH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cochlear's share price for today is A$316.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cochlear's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$5.321.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Cochlear's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:COH has been successfully added to your 